Blood Res.  2022 Sep;57(3):207-215. 10.5045/br.2022.2022089.

Early diagnosis of Gaucher disease in Korean patients with unexplained splenomegaly: a multicenter observational study

Affiliations
  • 1Department of Internal Medicine, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Korea.
  • 2Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
  • 3Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • 4Division of Hematology, Department of Internal Medicine, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • 5Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • 6Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea.
  • 7Department of Oncology/Hematology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Korea.
  • 8Division of Hematology and Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
  • 9Department of Internal Medicine, Inje University College of Medicine, Haeundae Paik Hospital, Busan, Korea.
  • 10Division of Hematology-Oncology, Department of Internal Medicine, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
  • 11Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea.
  • 12Department of Hematology-Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang, Korea.
  • 13Division of Hematology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
  • 14Division of Hematology/Oncology, Department of Internal Medicine, Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea.
  • 15Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Hospital, Seoul, Korea.
  • 16Department of Internal Medicine, Hemato-Oncology, Chosun University Hospital, Gwangju, Korea.
  • 17Division of Hematology/Oncology, Department of Medicine, Seoul National University College of Medicine, Seoul, Korea.
  • 18Samsung Medical Center, Seoul National University College of Medicine, Seoul, Korea.
  • 19Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.

Abstract

Background
Gaucher disease (GD) is an autosomal recessive disorder characterized by excessive accumulation of glucosylceramide in multiple organs. This study was performed to determine the detection rate of GD in a selected patient population with unexplained splenomegaly in Korea.
Methods
This was a multicenter, observational study conducted at 18 sites in Korea between December 2016 and February 2020. Adult patients with unexplained splenomegaly were enrolled and tested for β-glucosidase enzyme activity on dried blood spots (DBS) and in peripheral blood leukocytes. Mutation analysis was performed if the test was positive or indeterminate for the enzyme assay. The primary endpoint was the percentage of patients with GD in patients with unexplained splenomegaly.
Results
A total of 352 patients were enrolled in this study (male patients, 199; mean age, 48.42 yr). Amongst them, 14.77% of patients had concomitant hepatomegaly. The most common sign related to GD was splenomegaly (100%), followed by thrombocytopenia (44.32%) and, anemia (40.91%). The β-glucosidase activity assay on DBS and peripheral leukocytes showed abnormal results in sixteen and six patients, respectively. Eight patients were tested for the mutation, seven of whom were negative and one patient showed a positive mutation analysis result. One female patient who presented with splenomegaly and thrombocytopenia was diagnosed with type 1 GD. The detection rate of GD was 0.2841% (exact 95% CI, 0.0072‒).
Conclusion
The detection rate of GD in probable high-risk patients in Korea was lower than expected. However, the role of hemato-oncologists is still important in the diagnosis of GD.

Keyword

Acid β-glucosidase; Dried blood spot; Gaucher disease; Lysosomal storage disorder; Splenomegaly; Thrombocytopenia

Figure

  • Fig. 1 Flow diagram of the disposition of patients.

  • Fig. 2 Acid β-glucosidase assay and GBA gene mutation analysis results.

  • Fig. 3 Abdominal CT showing huge splenomegaly before enzyme replacement therapy (2017).

  • Fig. 4 Abdominal CT showing reduced size of the spleen after ERT (2021).


Reference

1. Grabowski GA. 2008; Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet. 372:1263–71. DOI: 10.1016/S0140-6736(08)61522-6. PMID: 19094956.
Article
2. Mistry PK, Cappellini MD, Lukina E, et al. 2011; A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol. 86:110–5. DOI: 10.1002/ajh.21888. PMID: 21080341. PMCID: PMC3058841.
Article
3. Kaplan P, Baris H, De Meirleir L, et al. 2013; Revised recommendations for the management of Gaucher disease in children. Eur J Pediatr. 172:447–58. DOI: 10.1007/s00431-012-1771-z. PMID: 22772880.
Article
4. Lee JY, Lee BH, Kim GH, et al. 2012; Clinical and genetic characteristics of Gaucher disease according to phenotypic subgroups. Korean J Pediatr. 55:48–53. DOI: 10.3345/kjp.2012.55.2.48. PMID: 22375149. PMCID: PMC3286762.
Article
5. Jeong SY, Park SJ, Kim HJ. 2011; Clinical and genetic characteristics of Korean patients with Gaucher disease. Blood Cells Mol Dis. 46:11–4. DOI: 10.1016/j.bcmd.2010.07.010. PMID: 20729108.
Article
6. Gary SE, Ryan E, Steward AM, Sidransky E. 2018; Recent advances in the diagnosis and management of Gaucher disease. Expert Rev Endocrinol Metab. 13:107–18. DOI: 10.1080/17446651.2018.1445524. PMID: 30058864. PMCID: PMC6129380.
Article
7. Thomas AS, Mehta AB, Hughes DA. 2013; Diagnosing Gaucher disease: an on-going need for increased awareness amongst haematologists. Blood Cells Mol Dis. 50:212–7. DOI: 10.1016/j.bcmd.2012.11.004. PMID: 23219328.
Article
8. Mistry PK, Sadan S, Yang R, Yee J, Yang M. 2007; Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. 82:697–701. DOI: 10.1002/ajh.20908. PMID: 17492645.
Article
9. Andrade-Campos MM, de Frutos LL, Cebolla JJ, et al. 2020; Identification of risk features for complication in Gaucher's disease patients: a machine learning analysis of the Spanish registry of Gaucher disease. Orphanet J Rare Dis. 15:256. DOI: 10.1186/s13023-020-01520-7. PMID: 32962737. PMCID: PMC7507684. PMID: 29234a24352744b8afb0e10a2ead564d.
Article
10. Yoo HW, Lee HJ, Kim DS, et al. 2014. Disease Management Guideline on LSD - 2. Gaucher disease. The Korean Society of Inherited Metabolic Disease & Medical Review;Seoul, Korea:
11. Motta I, Consonni D, Stroppiano M, et al. 2021; Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia. Sci Rep. 11:2594. DOI: 10.1038/s41598-021-82296-z. PMID: 33510429. PMCID: PMC7843616. PMID: b22675ddb7324d238338d5c54148d366.
Article
12. Charrow J, Andersson HC, Kaplan P, et al. 2000; The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 160:2835–43. DOI: 10.1001/archinte.160.18.2835. PMID: 11025794.
13. Motta I, Filocamo M, Poggiali E, et al. 2016; A multicentre observational study for early diagnosis of Gaucher disease in patients with splenomegaly and/or thrombocytopenia. Eur J Haematol. 96:352–9. DOI: 10.1111/ejh.12596. PMID: 26033455.
Article
14. Marchi G, Nascimbeni F, Motta I, et al. 2020; Hyperferritinemia and diagnosis of type 1 Gaucher disease. Am J Hematol. 95:570–6. DOI: 10.1002/ajh.25752. PMID: 32031266.
Article
15. Diaz GA, Gelb BD, Risch N, et al. 2000; Gaucher disease: the origins of the Ashkenazi Jewish N370S and 84GG acid beta-glucosidase mutations. Am J Hum Genet. 66:1821–32. DOI: 10.1086/302946. PMID: 10777718. PMCID: PMC1378046.
16. El-Beshlawy A, Tylki-Szymanska A, Vellodi A, et al. 2017; Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry. Mol Genet Metab. 120:47–56. DOI: 10.1016/j.ymgme.2016.12.001. PMID: 28040394.
Article
17. Kawame H, Eto Y. 1991; A new glucocerebrosidase-gene missense mutation responsible for neuronopathic Gaucher disease in Japanese patients. Am J Hum Genet. 49:1378–80. PMID: 1840477. PMCID: PMC1686467.
18. Stirnemann J, Vigan M, Hamroun D, et al. 2012; The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients. Orphanet J Rare Dis. 7:77. DOI: 10.1186/1750-1172-7-77. PMID: 23046562. PMCID: PMC3526516.
Article
19. Cozzolino I, Picardi M, Pagliuca S, et al. 2016; B-cell non-Hodgkin lymphoma and pseudo-Gaucher cells in a lymph node fine needle aspiration. Cytopathology. 27:134–6. DOI: 10.1111/cyt.12254. PMID: 26033037.
Article
20. Sharma P, Das R, Bansal D, Trehan A. 2015; Congenital dyserythropoietic anemia, type II with SEC23B exon 12 c.1385 A → G mutation, and pseudo-Gaucher cells in two siblings. Hematology. 20:104–7. DOI: 10.1179/1607845414Y.0000000166. PMID: 24801240.
Article
21. Chatterjee T, Dewan K, Ganguli P, et al. 2013; A rare case of hemoglobin E hemoglobinopathy with Gaucher's disease. Indian J Hematol Blood Transfus. 29:110–2. DOI: 10.1007/s12288-012-0153-z. PMID: 24426351. PMCID: PMC3636348.
Article
22. Ferreira CR, Gahl WA. 2017; Lysosomal storage diseases. Transl Sci Rare Dis. 2:1–71. DOI: 10.3233/TRD-160005. PMID: 29152458. PMCID: PMC5685203.
Article
23. Burton BK, Charrow J, Hoganson GE, et al. 2017; Newborn screening for lysosomal storage disorders in Illinois: the initial 15-month experience. J Pediatr. 190:130–5. DOI: 10.1016/j.jpeds.2017.06.048. PMID: 28728811.
Article
Full Text Links
  • BR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr